
éåœã®ç ç©¶ã«ãããšãCOVIDã¯ã¯ãã³æ¥çš®åŸ1幎以å ã«ãããçºçãããªã¹ã¯ã27ïŒ å¢å ããããšã倿ãã
å èšäºã¯ãã¡ããã/Click here to read the original article.
9æãéåœãœãŠã«åžåšäœã®840äžäººã®å¥åº·èšé²ãåæããç ç©¶ãçºè¡šããããããã«ãããšãæ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³æ¥çš®åŸ1幎以å ã«ãããçºçãããªã¹ã¯ãå šäœã§27ïŒ äžæããããšã倿ããã
ãã¯ã¯ãã³ãã®çš®é¡ã«ããå·®ã¯é¡èã§ãmRNAã¯ã¯ãã³æ¥çš®åŸã«ã¯ãããªã¹ã¯ã20ïŒ äžæããã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒã¯ã¯ãã³ïŒã¢ã¹ãã©ãŒãã«ãªã©ïŒæ¥çš®åŸã«ã¯50ïŒ äžæããã
ãã¹ãŠãå€ããããç ç©¶ââç¡èŠã§ããªãçµæ
ã¬ã€ã»ãããã£ãŒãå士 2025幎11æ11æ¥
2025幎9æ26æ¥ãåŠè¡èªãBiomarker Researchãã«ãCOVID-19ã¯ã¯ãã³æ¥çš®ã«é¢é£ããçã®1幎éãªã¹ã¯ïŒéåœã«ãããå€§èŠæš¡äººå£ããŒã¹ã³ããŒãç ç©¶ããšé¡ããç ç©¶è«æãæ²èŒããããæ¬ç ç©¶ã¯ãåœæ°å¥åº·ä¿éºå¶åºŠã«å å ¥ããéåœã»ãœãŠã«åžåšäœã®840äžäººã®å¥åº·èšé²ãåæããCOVIDã¯ã¯ãã³æ¥çš®è ãšæªæ¥çš®è ã«ãããççºççãæ¯èŒãããæ¬çš¿ã§ã¯ããã®ç ç©¶çµæã詳现ã«åæããå ¬å ±æ¿ç圢æã«äžå¯æ¬ ãªçµè«ãå°ãåºãã
æ¬ç ç©¶ã§ã¯ã2021幎ãã2023幎ã®éã«å°ãªããšã2åã®COVIDã¯ã¯ãã³æ¥çš®ãåãã人ã ã®ããçºççããæªæ¥çš®è ã®ããè»¢åž°ãšæ¯èŒãããå ·äœçã«ã¯ãã¯ã¯ãã³æ¥çš®å®äºåŸ12ãæéã®ã¯ã¯ãã³æ¥çš®è ã®ççºçç¶æ³ãšã2022幎12ãæéã®æªæ¥çš®è ã®çèšé²ãæ¯èŒããããœãŠã«äººå£ã®æªæ¥çš®è ã¯èš60äžäººïŒ8ïŒ ïŒã§ãã£ãã亀絡å åãæé€ããããã䞡矀ã¯å¹Žéœ¢ãæ§å¥ãä¿éºå å ¥ç¶æ³ã䜵åçŸæ£ã«ã€ããŠå³å¯ã«ãããã³ã°ããããéå»ã«ããæŽã®ããè ãæ°åã³ããã¯ã¯ãã³ã1åã®ã¿æ¥çš®ããè ïŒ30äžäººïŒã¯ç 究察象ããé€å€ãããããŸããç ç©¶æéäžã«æ»äº¡ããè ïŒ3äžäººïŒãã¯ã¯ãã³æ¥çš®èšé²ãäžå®å šãªè ïŒ7äžäººïŒãé€å€å¯Ÿè±¡ãšãªã£ãã
ã¯ã¯ãã³æ¥çš®çŸ€ã®çŽ80%ãmRNAã¯ã¯ãã³ïŒãã¡90%ããã¡ã€ã¶ãŒè£œïŒãæ¥çš®ã20%ã¯ã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒïŒcDNAïŒã¯ã¯ãã³ïŒäž»ã«ã¢ã¹ãã©ãŒãã«è£œïŒãŸãã¯æ··åã¯ã¯ãã³ãæ¥çš®ããã
ãã®å€§èŠæš¡ç ç©¶ã®äž»ãªç¥èŠã¯ä»¥äžã®éãïŒ
â¢ å šäœãšããŠãCOVIDã¯ã¯ãã³æ¥çš®åŸ1幎以å ã®ççºçãªã¹ã¯ã¯æªæ¥çš®çŸ€ãšæ¯èŒããŠ27%å¢å ããããã®ãªã¹ã¯ã¯ãããã®çš®é¡ãã¯ã¯ãã³çš®é¡ã«ãã£ãŠåçã«ååžããŠããªãã£ãã
⢠ç²ç¶è ºããã¯35%ãèããã¯21%ãå€§è žããã¯28%ãèºããã¯53%ãä¹³ããã¯20%ãåç«è ºããã¯69%ã®çžå¯Ÿãªã¹ã¯å¢å ãèªããããããã®ä»ã®ççš®ã«ã€ããŠã¯ã95%ä¿¡é Œåºéã«åãŸãããèšåºçã«ææãªçãªã¹ã¯ã瀺åãããã®ã§ã¯ãªãã£ãã
â¢ å šççš®ã®ãªã¹ã¯ã¯ãmRNAã¯ã¯ãã³æ¥çš®ã§ã¯20%ãã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒã¯ã¯ãã³æ¥çš®ã§ã¯50%ã§ãã£ããèçãšåç«è ºçã®ãªã¹ã¯å¢å ã¯ã¢ãããŠã€ã«ã¹ã¯ã¯ãã³ã«ã®ã¿èªããããä¹³çãªã¹ã¯ã®å¢å ã¯mRNAã¯ã¯ãã³ã«ã®ã¿èªãããããçµ±èšçã«ææãªãã®ä»ã®ççš®ïŒç²ç¶è ºçãèºçãå€§è žçïŒã®ãªã¹ã¯å¢å ã¯ãäž¡ã¿ã€ãã®ã¯ã¯ãã³ã§èªããããã
⢠ãã¡ã€ã¶ãŒè£œmRNAããŒã¹ã¿ãŒæ¥çš®ãåããè ã¯ã2åæ¥çš®ã®ã¿ã®å Žåãããèçãªã¹ã¯ãããã«é«ãã£ããå ããŠãèµèççºçã®èšåºçã«ææãªãªã¹ã¯ãèªãããããã®çµæã¯æ¥æ¬ã®å¥åº·ããŒã¿ã§åŸãããç¥èŠãšé¡äŒŒããŠããã
⢠ãœãŠã«äœæ°ã®ã»ãŒå šå¡ïŒ98%ïŒãåœæ°å¥åº·ä¿éºå¶åºŠã«å å ¥ããŠããäºå®ãããæ¬ç ç©¶çµæã¯éžæãã€ã¢ã¹ã®åœ±é¿ãåããªããããã¯ãªã¹ã¯ãå®èšŒãã人å£ããŒã¹ã®COVID-19ç ç©¶ãéå»ã«ææãããæ¹å€ç¹ã§ããã峿äºé²æªçœ®ãžã®åè«ãæé€ãããã®ã§ããã

ããããå¯èœæ§ãç¶²çŸ ããç ç©¶ã¯ååšããªãïŒ
⢠äžéšã®ããã¯çºçãŸã§ã«æ°å¹ŽãèŠãããæ¬ç ç©¶ã¯COVIDã¯ã¯ãã³æ¥çš®åŸ1幎以å ã®ããçºççã®ã¿ã察象ãšãããããã¯COVIDã¯ã¯ãã³ã«é¢é£ãåŸãããã®åŸçºæ§çºçãåŠå®ãããã®ã§ã¯ãªãã
⢠äžéšã®ããã¯æªæ€åºã®ãŸãŸæ®ãããããã£ãŠå®éã®ããçºççã¯å ±åå€ãäžåãå¯èœæ§ãããã
⢠æ¬ç ç©¶ã¯ãè±ç±³ã®èåãªè «çåŠè ããææããçŸè±¡ã§ãããCOVIDã¯ã¯ãã³æ¥çš®åŸã®ããåçºäºäŸãå«ãã§ããªãã
⢠COVIDã¯ã¯ãã³æ¥çš®ãšãããªã¹ã¯äžæã®é¢é£æ§ã¯åççãªçãã®äœå°ãªã蚌æãããŠãããã®ã®ãã¯ã¯ãã³æ¥çš®åŸã®ããçºçã¡ã«ããºã ã¯äŸç¶ãšããŠäžæçãã€æªç¥ã®éšåãå€ãããã®ããç ç©¶èè ãã¯ãé¢äžããå ·äœçãªã¡ã«ããºã ãçè§£ããã«COVIDã¯ã¯ãã³æ¥çš®åŸã®ããçºçãªã¹ã¯ãæçµçã«å æé¢ä¿ãšããŠç¢ºç«ããããšã¯ã§ããªããšã®èŠè§£ã«åºã¥ãå 責äºé ãå ¬è¡šããããšã決å®ããããã®ãããªå 責äºé ã®èšèŒã¯ãCOVIDé¢é£ç ç©¶ã§ã¯åžžæ åããŠããããªããªãããããèšèŒããªããã°åŠè¡èªã®æ»èªããã»ã¹ãééããå¯èœæ§ã極ããŠäœãããã ãèšãæããã°ãç§åŠçããã€ãªãã¯ãããžãŒå®éšãæ¯æããååã«ãããããŒã¿ãäœã瀺ãããšã絶察çãªãªã¹ã¯ã瀺åãããããã䞻匵ã¯åŽäžãããããããŠãã®ããŒã¿ã¯æ±ºå®çã«äžå©ãªãã®ã§ããã
⢠ããã¯æ»äº¡åå ã®ç¬¬2äœã§ããããCOVIDã¯ã¯ãã³æ¥çš®ã¯ç¹å®ã®å¿çŸæ£ãç¥çµçŸæ£ãè èç ã粟ç¥çŸæ£ã®çºççäžæãšãé¢é£ããŠããããšãç¥ãããŠããããããã£ãŠãCOVIDã¯ã¯ãã³æ¥çš®åŸã®ç¹å®ã®é節ãªçŸæ£ãªã¹ã¯ã¯ããããªã¹ã¯åç¬ãããã¯ããã«é«ãã
ããã¯å ¬è¡è¡çæ¿çãšã¯ã¯ãã³èŠå¶ã«é倧ãªåœ±é¿ãåãŒãéåžžã«å€§èŠæš¡ãªç ç©¶ã§ãããã§ã¯ãå°éå®¶ããžã£ãŒããªã¹ãã®åå¿ã¯ã©ãã ã£ãã®ãïŒ
ãã®ç ç©¶ã§ã¯ãCOVIDã¯ã¯ãã³æ¥çš®ãæªæ¥çš®è ãšæ¯èŒããŠçãªã¹ã¯å¢å ãšçµ±èšçã«ææãªé¢é£æ§ã瀺ãããšã倿ããã«ããããããããã®çµæã¯äŒæ¥ã¡ãã£ã¢ã«ãã£ãŠã»ãŒç¡èŠãããå Žåã«ãã£ãŠã¯åŠå®ãŸãã¯è»œèŠãããŠãããCOVIDã¯ã¯ãã³ããã€ãªãã¯ãããžãŒã®å¥è·¡ã§ãããšããèãã¯ãæ¿åºçºè¡šãææã¡ãã£ã¢ã«ãã宣äŒãéããŠãå ¬è¡ã®æèã«æ·±ãæ ¹ä»ããŠãããããã«ãç ç©¶ç§åŠè ãã¡ã¯ãã€ãªãã¯ãããžãŒç ç©¶ã®å°æ¥ã«å€å€§ãªæè³ãè¡ã£ãŠããããã®åèŠãšãã€ãªãã¯ãããžãŒã®å®å šæ§ã»æå¹æ§ã«é¢ããå å ¥èŠ³ã¯ããã®èŠæš¡ãšçµ±èšçç¢ºå®æ§ãåããç ç©¶ã«ãã£ãŠããããéåžžã«ææãã«ããããšãæããã«ãªã£ãŠããã
äŸãã°ãã«ããã®åŸ®çç©åŠè ãã³ã©ã€ã»ã©ã·ã§ã¯å士ã®YouTubeåç»ã¯ãçµæã®è§£éã«æ éããä¿ãããããªãç ç©¶ãæ±ããŠããã圌ã¯ãã®çºèŠããæ²ããç¥ããããšè¡šçŸãã€ã€ããå šäœçãªãããªã¹ã¯ããäœãããšè©ããŠå®å¿æã瀺ããŠããïŒçžå¯Ÿãªã¹ã¯ã27%ãäžæããããšãæ¬åœã«ãäœãããšèšããã®ã???ïŒã圌ã¯ã³ããã¯ã¯ãã³æ¥çš®ã®äžæ¢ãæ±ãããããããä»åŸãããå¢å åŸåãç¶ããšäºæ³ãããããšèªããŠããã
ãããŠãé¢äžããæ£ç¢ºãªã¡ã«ããºã ã®è§£æãç¶ç¶ãããšèªçŽããŠãããã€ãŸãããããªã¹ã¯äžæã®æ ¹æ¬ã¡ã«ããºã ãäžæã§ããããšããèŠæã§ã¯ãªããããªããã€ãªãã¯ãããžãŒç ç©¶ã®çç±ãšèŠãªãããŠããã®ã ã
ãã®çš®ã®å¯Ÿå¿ã®æãã¹ãè匱æ§ã¯èª°ã®ç®ã«ãæããã§ããïŒç§åŠè ãCOVIDã¯ã¯ãã³ïŒãããŠããããçŸåšéçºäžã®ä»ã®mRNAã¯ã¯ãã³ïŒã®äººéã»åç©ãžã®åœ±é¿ãç ç©¶ãç¶ããéãå ¬è¡ãå¢å ãããããªã¹ã¯ã®è² æ ãèè² ããããããšãæåŸ ãããŠãããæããŠéé£ãããã¹ãææ¡ã ã
ãã¥ãŒãžãŒã©ã³ãæ¿åºãåæ§ã«ãmRNAã¯ã¯ãã³ç ç©¶ããã®ä»ã®ãªã¹ã¯ã䌎ããã€ãªãã¯ãããžãŒç ç©¶ãæšé²ããæ±ºæã瀺ããŠããã11æ5æ¥ãæ¿åºæ¯æŽã®ããŒã·ã¥ãã³åºéã¯ããã¯ããªã¢å€§åŠãšãã©ã¬ã³ç ç©¶æã®ããŒã ã«å¯Ÿããæ°ããªmRNAã¯ã¯ãã³ã®ç ç©¶ã®ããã«100äžãã«ã®å©æéãæäžããã
ãã®éåœç ç©¶ã¯ãèåãªå¿èå°éå»ããŒã¿ãŒã»Aã»ããã«ã©ãå士ãã¢ã·ãŒã ã»ãã«ããã©å士ãªã©ãCOVIDã¯ã¯ãã³å®å šæ§ãžã®æžå¿µãç¹°ãè¿ã衚æããŠããç§åŠè ãã¡ã«ãã£ãŠããœãŒã·ã£ã«ã¡ãã£ã¢äžã§å€§èŠæš¡ãªæ³šç®ãéããããããã¢ã«ãžã£ãžãŒã©ãªã©äžéšã¡ãã£ã¢ã¯ãéåœç ç©¶ã¯æ¬åœã«COVID-19ã¯ã¯ãã³ãçãåŒãèµ·ãããšäž»åŒµããã®ãïŒã ãšãã£ãèŠåºããæ²ããã¢ã«ãžã£ãžãŒã©ãªã©äžéšã¡ãã£ã¢ã¯ããã®ç ç©¶ã瀺ããŠããã®ã¯åãªããåŸåãã«éããã圌ãã®ç¡ç¥ãªèŠè§£ã§ã¯ã人éã察象ãšãããããªãç ç©¶ãå¿ èŠããšç€ºåããŠããã ãã ãšãã誀ã£ã䞻匵ã®ã¿ã«åºã¥ããŠãäºå®ã«åºã¥ã蚌æ ãéããŠãããããããç²ç®çã§èª€è§£ãæãæ¹å€ã«ãããããããç ç©¶çµæã¯ç§åŠçã«ç¢ºåºãšããŠä¿¡é Œã§ãããã®ã§ãããå®å šã«ç¡èŠããããšã¯ã§ããªããæ£æ°ã®è ãªã誰ãããã¯ããªãã ããããã®ç ç©¶ã¯åé¡ã®æ žå¿ãçªããŠããã®ã ã
COVID-19æä»£ã«éçºããããã€ãªãã¯ãããžãŒã®å»çå¿çšã¯ãæ¬è³ªçã«ãªã¹ã¯ãé«ãå®å šã§ãªãããšã極ããŠæçœã§ããã
蚌æ åéãçµãå ±åæžäœææ®µéã«ç§»è¡ããCOVID-19çç«å§å¡äŒç¬¬2段éã«å¯Ÿããæ¬ç ç©¶ã®ç€ºåããæã¯æç¢ºãã€å匷ãäŒããããã¹ãã§ãããå§å¡ãã¡ã¯äžå¯è§£ãªçç±ã§ç§åŠç蚌æ ã®èª¿æ»ã»è©äŸ¡ãè¡ããªãããšã決å®ããããã調æ»ããŠããã°ãçŸåšæ€èšäžã®çµè«ãšã¯å€§ããç°ãªãçµæãšãªã£ãŠããã ãããCOVID-19ã¯ã¯ãã³ã«ã¯ããããã®ä»ã®é節ãªçŸæ£ãªã¹ã¯ã䌎ãããã®ãªã¹ã¯ã¯äžä»£ãè¶ ããŠæç¶ãããå§å¡äŒã¯äºå®äžã蚌æ ãç¡èŠããéžæãããåœæ°ãæéãšå±éºã®äžã«çœ®ãå»ãã«ããã®ã§ããã
ãã¥ãŒãžãŒã©ã³ãã§ã¯éå»5幎éã«ãæ°åã³ããã¯ã¯ãã³æ¥çš®ãæåŠããŠããå Žåãæ¥çš®çŸ©åã®å¯Ÿè±¡ãšãªã£ãŠããªãã£ããªãã°çºçããªãã£ãã§ãããçæ£è ãçžåœæ°çºçããŠããå¯èœæ§ãããã
äžè¬åžæ°ã¯ãæ°åã³ããã¯ã¯ãã³ãå«ããã€ãªãã¯ãããžãŒå®éšã«äŒŽããªã¹ã¯ã®æ§è³ªããå€ãã®éèŠãªç¹ã§ç¬ç¹ã§ããããšãèªèããŠããªããããããªããäŸãã°ãæ°åã³ããã¯ã¯ãã³ã®éºäŒåé åãæ¥çš®è ã®DNAã«çµã¿èŸŒãŸããäºäŸã確èªãããŠããããã®æå³ã§ããã®åœ±é¿ã¯å°ã蟌ãããããååã軜æžãäžå¯èœã§ãããäžä»£ãè¶ ããŠåœ±é¿ãæ³¢åããå¯èœæ§ããããåœæ¹ã¯Substack.comã®èšäºã§ããã€ãªãã¯ãããžãŒå®éšãå®å šã«æåŠãã¹ã20ã®çç±ããå«ããªã¹ã¯ã«ã€ããŠè©³çްã«è«ããŠããã
ãã®åé¡ã«ãããŠäžç«ã®ç«å Žãåãããšã¯äžå¯èœã§ãã
ãã€ãªãã¯ãããžãŒå®éšã¯ãæã ãç¥ãçåœãšå®å šã«å ±åããããšã¯ã§ããªããããã¯æ°åå幎ã«ãããé²åéçšãéããŠç¢ºç«ãããèªç¶ã®ç§©åºãšåè¡¡ãšççŸããã人éã®å¥åº·ãå«ãçžäºã«æ¯ãåãå°ççæ ç³»ã¯ãéºäŒåéã®é¢ä¿æ§ã«äŸåããŠããããã®é¢ä¿æ§ã¯ãã€ãªãã¯ãããžãŒå®éšã«ãã£ãŠå¿ ç¶çã«ç Žå£ããããããã¯æŠæŒ¢ãä»å°åã§é²è¡äžã§ããä»ãç¶ãæ°åçŸç ã®åµåºããããã¯äžçäžã§å éããçç©ã®éºäŒåæ¹å€ãéããŠèµ·ããã ããã
ãšã€ãã©ãã ã»ãªã³ã«ãŒã³ã®èšèãåããã°ïŒãåè£ããå®¶ã¯ç«ã¡è¡ããªãâŠãããã¯å šãŠãäžæ¹ã仿¹ãšãªãã
ãã€ãªãã¯ãããžãŒå®éšã¯å°ã蟌ãããããèªç¶çºçããéºäŒçããã»ã¹ãšå ±åã§ããªãââããã¯ç Žæ» çãªçµæãããããæã ãå§åããã ãããéåœã®ããç ç©¶ã®èšŒæ ã¯æªæ¥ã®ã¹ã¯ãªãŒã³ã«å€§ããæ ãåºãããŠããããã®çºèŠãç¡èŠãããå²ç¬ãããããŠã眰ããããªããšèããè ã¯ãçåœã®æå³ãä¿è·ã®å¿ èŠæ§ã倱ã£ãŠããã
ãã¥ãŒãžãŒã©ã³ãéºäŒåæè¡æ³æ¡ã«ããããã€ãªãã¯ãããžãŒå®éšã®èŠå¶ç·©åææ¡ã¯ãåãªãç¡è¬ã§ã¯ãªãèªæ®ºè¡çºã§ããã誰ãå芳ããŠãããèš±ããçŸå®ã®èšèšãç¡ç¥ãªæ¿åºãè²·åãããã¡ãã£ã¢ãå ¬è¡è¡çãšäººåœãžã®ãªã¹ã¯ã軜ã ããåãå ¥ããç§åŠè ã«å§ããã¹ãã§ã¯ãªããæŽå²ã®ãã®ç¬éã«ãã以äžã®ç¯çœªã¯ããããªãããOur World in Dataãã®æšèšã«ããã°ãéå»5幎éã§äžççã«3000äžäººã®éå°æ»äº¡ãçºçãããç¬¬äºæ¬¡äžç倧æŠä»¥æ¥ãããã»ã©ã®èŠæš¡ã®ãã®ã¯ãªãã£ãã人é¡ã«å¯Ÿããæ°ããªæŠäºãé²è¡äžã ãããã¯ãã€ãªãã¯ãããžãŒã®å°éçšèªãšå¥åº·ãžã®èª€è§£ãæãçŽæã«ãã£ãŠåœè£ ãããŠãããçå®ã¯å·§åŠã«é èœãããŠãããæã ã¯æ¬ºãããŠããã®ã ã